Últimas noticias sobre Celestica (NYSE:CLS) Bolsa

Celestica

Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity & Cloud Solutions segment.

Celestica Inc

Exchange Listed Funds Trust Cabana Target Leading Sector Aggressive ETF

Exchange Listed Funds Trust Cabana Target Leading Sector Conservative ETF

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical Inc

Trust for Professional Managers Convergence Long/Short Equity ETF

CLS HOLDINGS USA INC by CLS Holdings USA, Inc.

CLS Holdings USA Inc

Cleanspark Inc

Cabana Target Leading Sector Moderate ETF

CANADIAN LIFE COS SPLT by CANADIAN LIFE COS SPLIT CORP.

Canadian Life Companies Split Corp

Catalyst Bancorp Inc

CHINA OIL & GAS GROUP LTD by China Oil & Gas Group, Ltd.

China Oil And Gas Group Ltd

WIIM

Celestica shares are trading lower after UBS initiated coverage on the stock with a Neutral rating and announced a price target of $95.

In the latest quarter, 8 analysts provided ratings for Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $74.88, a high estimate of $95.00, and a low estimate of $58.00. Witnessing a positive shift, the current average has risen by 20.13% from the previous average price target of $62.33.
<img src="https://www.benzinga.com/files/images/story/2024/1732287615_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Celestica by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$91.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Chan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Paul Treiber</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Thanos Moschopoulos</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Daniel Chan</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celestica. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Celestica compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Celestica's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Celestica's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Celestica analyst ratings.</a>
<h2>Unveiling the Story Behind Celestica</h2>
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity &amp; Cloud Solutions segment.
<h3>Celestica: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Celestica's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 22.33%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Celestica's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.67% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.06%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Celestica's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.55% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.52, Celestica adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Ratings For Celestica

UBS analyst David Vogt initiates coverage on Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Neutral rating and announces Price Target of $95.

News

Price Target

Initiation

UBS Initiates Coverage On Celestica with Neutral Rating, Announces Price Target of $95

Investors with a lot of money to spend have taken a bearish stance on Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CLS, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 13 options trades for Celestica.
This isn't normal.
The overall sentiment of these big-money traders is split between 46% bullish and 53%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $29,000, and 12, calls, for a total amount of $3,259,794.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $27.5 to $100.0 for Celestica over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Celestica stands at 542.89, with a total volume reaching 7,498.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Celestica, situated within the strike price corridor from $27.5 to $100.0, throughout the last 30 days.
<h3>Celestica 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732043739_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.3</td>
<td>$21.6</td>
<td>$22.1</td>
<td>$85.00</td>
<td>$2.2M</td>
<td>3.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$23.0</td>
<td>$22.3</td>
<td>$22.4</td>
<td>$62.50</td>
<td>$257.6K</td>
<td>453</td>
<td>130</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$57.0</td>
<td>$54.8</td>
<td>$57.0</td>
<td>$27.50</td>
<td>$171.0K</td>
<td>122</td>
<td>30</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.15</td>
<td>$2.05</td>
<td>$2.05</td>
<td>$95.00</td>
<td>$153.7K</td>
<td>304</td>
<td>762</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$15.9</td>
<td>$15.3</td>
<td>$15.3</td>
<td>$80.00</td>
<td>$87.2K</td>
<td>37</td>
<td>583</td>
</tr>
</tbody>
</table>

<h3>About Celestica</h3>
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity &amp; Cloud Solutions segment.
In light of the recent options history for Celestica, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Celestica Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,051,582, the CLS's price is up by 3.49%, now at $86.9. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 69 days.</li>
</ul>
<h3>Expert Opinions on Celestica</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $75.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays has revised its rating downward to Overweight, adjusting the price target to $91. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Celestica, which currently sits at a price target of $72. 
&#x2A; An analyst from Stifel persists with their Buy rating on Celestica, maintaining a target price of $70. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Celestica with a target price of $75. 
&#x2A; An analyst from TD Cowen persists with their Buy rating on Celestica, maintaining a target price of $70. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Celestica options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Spotlight on Celestica: Analyzing the Surge in Options Activity

AEIS

ALGM

ANET

AVGO

AWRE

BELFB

BOXL

CAMT

CGNX

CLMB

CMTL

CNXN

COHR

CSCO

DELL

DGII

DIOD

EVLV

EXTR

FFIV

FLEX

FORM

FRSH

IONQ

IPGP

KEYS

KODK

LASR

LITE

NOVT

NTAP

NTCT

NVEC

Next Technology Holding Inc. - Ordinary Shares

NXTT

OSIS

PLUS

PLXS

PMTS

PSTG

QMCO

QTWO

SANM

SCSC

SITM

TTMI

VIAV

WOLF

ZBRA

Shares of companies within the broader technology sector are trading higher in sympathy with overall market strength after Donald Trump was elected president of the United States.

Celestica shares are trading higher after Barclays initiated coverage on the stock with an Overweight rating and announced a price target of $91.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/64f99e440313770001b5ef69/george-wang">Barclays analyst George Wang</a> initiated coverage on Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with an Overweight rating and announced a price target of $91. Celestica shares closed at $72.32 on Monday. <a href="https://www.benzinga.com/quote/CLS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Tessa Romero initiated coverage on Upstream Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) with an Overweight rating and announced a price target of $38. Upstream Bio shares closed at $25.15 on Monday. <a href="https://www.benzinga.com/quote/UPB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5901e8ea0bd9910001e193f8/margaret-kaczor">William Blair analyst Margaret Kaczor</a> initiated coverage on CeriBell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) with an Outperform rating. CeriBell shares closed at $26.24 on Monday. <a href="https://www.benzinga.com/quote/CBLL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith initiated coverage on CMS Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>) with a Buy rating and announced a price target of $76. CMS Energy shares closed at $68.39 on Monday. <a href="https://www.benzinga.com/quote/CMS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Chad Dillard initiated coverage on Eaton Corporation plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) with an Outperform rating and announced a price target of $382. Eaton shares closed at $331.13 on Monday. <a href="https://www.benzinga.com/quote/ETN/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ETN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05080021/image-28-1024x534.png" alt="" class="wp-image-630210" style="width:662px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05080021/image-28-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05080021/image-28-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05080021/image-28-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05080021/image-28.png 1261w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41740698/top-3-health-care-stocks-youll-regret-missing-in-november">Top 3 Health Care Stocks You&#8217;ll Regret Missing In November</a></li>
</ul>

Pre-Market Outlook

Trading Ideas

CBLL

This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Barclays analyst George Wang initiates coverage on Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Overweight rating and announces Price Target of $91.

Barclays Initiates Coverage On Celestica with Overweight Rating, Announces Price Target of $91

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) stock upped 49.86% after the company announced it dosed its first patients in its Phase 1 clinical study of CAR-NK cell therapy for relapsed <a href="https://www.benzinga.com//node/41516867" target="_blank" rel="noreferrer noopener">B-Cell Non-Hodgkin Lymphoma</a>.</li>
<li>Stride, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) shares rocketed 41.43% after the company reported better-than-expected first-quarter results and issued FY25 and second-quarter <a href="https://www.benzinga.com//node/41487340" target="_blank" rel="noreferrer noopener">revenue guidance above estimates</a>. Analysts boosted the <a href="https://www.benzinga.com/quote/lrn/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) <a href="https://www.benzinga.com//node/41409452" target="_blank" rel="noreferrer noopener">shares jumped 32.21%</a>.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) stock gained 31.68% last week. The stock has been volatile ahead of the upcoming U.S. election.</li>
<li>ZEEKR Intelligent Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) gained 29.31%. Several U.S.-listed Chinese stocks gained after the People's Bank of China <a href="https://www.benzinga.com//node/41547149" target="_blank" rel="noreferrer noopener">injected 700 billion yuan</a> ($98.36 billion) into the banking system through its one-year medium-term lending facility, keeping the rate steady at 2.0%.</li>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) stock gained 27.52%.</li>
<li>Herc Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>) shares upped 21.76% after the company reported better-than-expected third-quarter revenue results and raised its FY24 equipment <a href="https://www.benzinga.com//node/41455862" target="_blank" rel="noreferrer noopener">rental revenue growth outlook</a>.</li>
<li>TeraWulf Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) stock gained 18.59% amid the rise in Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price. The company also proposed to raise $425 million via convertible senior debt notes.</li>
<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) stock escalated 20.76% after the company announced that it was granted FDA clearance for its 510(k) submission related to prior design changes <a href="https://www.benzinga.com//node/41462205" target="_blank" rel="noreferrer noopener">made to the Zio AT device</a>.</li>
<li>Celestica, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) shares rose 19.99% after the company reported better-than-expected third-quarter results and issued Q4 revenue guidance above estimates. Several analysts raised <a href="https://www.benzinga.com//node/41523564" target="_blank" rel="noreferrer noopener">the price target on the stock</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41560908/tesla-li-auto-and-microstrategy-are-among-top-10-large-cap-gainers-last-week-oct-21-oct-25-are-the" target="_blank" rel="noreferrer noopener">Tesla, Li Auto And MicroStrategy Are Among Top 10 Large Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41561358/genuine-parts-company-universal-health-services-and-topbuild-are-among-top-10-large-cap-losers-las" target="_blank" rel="noreferrer noopener">Genuine Parts Company, Universal Health Services, And TopBuild Are Among Top 10 Large Cap Losers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Mid Cap

Movers

$BTC

IBRX

IRTC

WULF

Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?

TD Cowen analyst Daniel Chan maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Buy and raises the price target from $68 to $70.

TD Cowen Maintains Buy on Celestica, Raises Price Target to $70

Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Celestica and provided 12-month price targets. The average target is $68.6, accompanied by a high estimate of $75.00 and a low estimate of $58.00. Marking an increase of 12.09%, the current average surpasses the previous average price target of $61.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1729785650_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Celestica is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Paul Treiber</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Thanos Moschopoulos</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Daniel Chan</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Celestica. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celestica compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Celestica's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Celestica's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Celestica analyst ratings.</a>
<h2>Get to Know Celestica Better</h2>
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity &amp; Cloud Solutions segment.
<h3>Celestica's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Celestica's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 23.33%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Celestica's net margin is impressive, surpassing industry averages. With a net margin of 4.16%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Celestica's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.67%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Celestica's ROA stands out, surpassing industry averages. With an impressive ROA of 1.72%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.53, Celestica adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Celestica: Insights From 5 Analyst Reviews

Stifel analyst Matthew Sheerin maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Buy and raises the price target from $58 to $70.

Stifel Maintains Buy on Celestica, Raises Price Target to $70

RBC Capital analyst Paul Treiber maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Outperform and raises the price target from $65 to $75.

RBC Capital Maintains Outperform on Celestica, Raises Price Target to $75

U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Thursday.
Shares of United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) rose during Thursday's session after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41515619/delivery-giant-ups-breaks-revenue-miss-streak-after-10-quarters-stock-soars">better-than-expected quarterly EPS and sales.</a>
UPS reported consolidated revenue growth of 5.6% year-over-year to $22.2 billion, beating the consensus of $22.14 billion. Adjusted EPS was $1.76, up 12.1% YoY, above the consensus of $1.63.
United Parcel Service shares jumped 5% to $137.93 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares jumped 31.6% to $6.82 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) gained 22.8% to $337.89 after the company reported better-than-expected third-quarter financial results.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) climbed 20.7% to $345.82 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates. Also, the company increased its fourth-quarter dividend.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) gained 18.7% to $71.65 after the company reported better-than-expected third-quarter EPS results.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) gained 17.7% to $14.67 after the company reported better-than-expected third-quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) surged 16.8% to $12.09 after the company provided updates on hurricane loss amounts and announced it expects a positive net income for the third quarter.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 16.5% to $248.93 following better-than-expected quarterly earnings.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) climbed 15.6% to $66.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 15.2% to $33.33 after the company presented data from its ongoing Phase 1a/1b study of ZL-1310 for previously treated extensive-stage small cell lung cancer at the EORTC-NCI-AACR Symposium 2024.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) gained 14.2% to $79.66.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) surged 13.2% to $29.72 after the company announced it bagged a contract with the Space Development Agency as the prime contractor to the US Government.</li>
<li>ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) gained 11.2% to $7.70 after the company reported better-than-expected third-quarter financial results and issued FY24 adjusted EPS above estimates.</li>
<li>Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) rose 10% to $109.18 following a third-quarter EPS beat and guidance above consensus estimates.</li>
<li>Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) rose 9.9% to $149.00 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 9.9% to $12.00 after Keybanc maintained an Overweight rating on the stock and raised its price target from $11 to $12.</li>
<li>CBRE Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NASDAQ">CBRE</a>) gained 9.7% to $135.12 after the company reported better-than-expected third-quarter financial results and raised its FY24 adjusted EPS guidance above estimates.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) rose 8.2% to $629.72 following upbeat quarterly earnings.</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) gained 7.6% to $236.52 following strong quarterly earnings.</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) gained 7.5% to $377.11 following strong quarterly sales.</li>
<li>T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) gained 4.1% to $230.00 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

Intraday Update

ACIC

ASTS

CBRE

Laboratory Corporation Of America Holdings

PEGA

POOL

RKLB

TMUS

TSLA

VKTX

ZLAB

UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday

BMO Capital analyst Thanos Moschopoulos maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Outperform and raises the price target from $64 to $72.

BMO Capital Maintains Outperform on Celestica, Raises Price Target to $72

<h3>Gainers</h3>
<ul>
<li>CCSC Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) shares moved upwards by 75.3% to $3.05 during Thursday's pre-market session. The company's market cap stands at $35.3 million. </li>
<li>ZenaTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) shares increased by 40.9% to $2.48. The market value of their outstanding shares is at $43.8 million. </li>
<li>Sanmina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) stock increased by 14.67% to $75.0. The market value of their outstanding shares is at $4.0 billion. </li>
<li>MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) shares rose 11.16% to $16.53. The market value of their outstanding shares is at $1.3 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) shares rose 8.32% to $62.25. The company's market cap stands at $7.3 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) stock rose 6.06% to $77.28. The market value of their outstanding shares is at $100.1 billion. As per the news, the Q1 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) stock declined by 63.7% to $2.76 during Thursday's pre-market session. The company's market cap stands at $63.9 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock declined by 29.95% to $0.1. The company's market cap stands at $2.0 million. </li>
<li>Zapata Computing Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) shares declined by 19.06% to $0.07. The company's market cap stands at $2.8 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares fell 11.09% to $0.26. The market value of their outstanding shares is at $1.9 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock decreased by 5.52% to $0.56. The market value of their outstanding shares is at $55.0 million. </li>
<li>Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) stock declined by 5.24% to $13.4. The company's market cap stands at $151.9 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CCTG

LRCX

MLGO

ORKT

PHUN

SVRE

ZENA

ZPTA

12 Information Technology Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>CCSC Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) stock moved upwards by 77.0% to $3.08 during Thursday's pre-market session. The market value of their outstanding shares is at $35.6 million. </li>
<li>ZenaTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) shares moved upwards by 39.72% to $2.46. The market value of their outstanding shares is at $43.4 million. </li>
<li>Sanmina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) shares rose 14.67% to $75.0. The company's market cap stands at $4.0 billion. </li>
<li>MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) stock rose 11.16% to $16.53. The market value of their outstanding shares is at $1.3 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) stock moved upwards by 9.79% to $63.1. The company's market cap stands at $7.4 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) stock rose 6.03% to $0.33. The market value of their outstanding shares is at $32.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) stock fell 63.1% to $2.81 during Thursday's pre-market session. The company's market cap stands at $65.0 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock decreased by 29.95% to $0.1. The market value of their outstanding shares is at $2.0 million. </li>
<li>Zapata Computing Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) stock decreased by 20.05% to $0.07. The market value of their outstanding shares is at $2.8 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock decreased by 10.74% to $0.26. The market value of their outstanding shares is at $1.9 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock fell 5.52% to $0.56. The company's market cap stands at $55.0 million. </li>
<li>Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) stock declined by 4.88% to $13.45. The company's market cap stands at $152.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MOVE

Celestica shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 revenue guidance above estimates.

<h3>Gainers</h3>
<ul>
<li>Rimini Street (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMNI#NASDAQ">RMNI</a>) stock rose 18.9% to $2.01 during Wednesday's after-market session. The market value of their outstanding shares is at $182.3 million. </li>
<li>Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) shares increased by 8.23% to $62.2. The market value of their outstanding shares is at $7.3 billion. As per the press release, Q3 earnings came out today. </li>
<li>MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) stock rose 7.98% to $16.06. The company's market cap stands at $1.3 billion. As per the press release, Q3 earnings came out today. </li>
<li>Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) stock rose 6.63% to $0.77. The company's market cap stands at $13.9 million. </li>
<li>Blackboxstocks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBX#NASDAQ">BLBX</a>) stock increased by 6.16% to $3.1. The company's market cap stands at $10.9 million. </li>
<li>Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) shares moved upwards by 5.16% to $76.62. The company's market cap stands at $99.3 billion. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock fell 30.1% to $0.1 during Wednesday's after-market session. The company's market cap stands at $2.0 million. </li>
<li>TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) stock declined by 8.13% to $5.88. The market value of their outstanding shares is at $2.2 billion. </li>
<li>SatixFy Communications (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SATX#AMEX">SATX</a>) stock decreased by 5.42% to $0.7. The company's market cap stands at $58.5 million. </li>
<li>Verb Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) stock declined by 4.64% to $10.45. The company's market cap stands at $7.6 million. </li>
<li>IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) stock decreased by 4.53% to $222.22. The company's market cap stands at $204.6 billion. The company's, Q3 earnings came out today. </li>
<li>Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares declined by 4.27% to $0.71. The company's market cap stands at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLBX

INTZ

RMNI

SatixFy Communications Ltd. Ordinary Share

SATX

VERB

VRAR

12 Information Technology Stocks Moving In Wednesday's After-Market Session

Barclays analyst George Wang CFA initiated coverage with a Buy rating on Celestica (CLS – Research Report) today and set a price target of $91.00. ...

Celestica (CLS) Receives a Buy from Barclays

Barclays analyst George Wang initiated coverage of Celestica (CLS) with an Overweight rating and $91 price target As a North American tier 1 electr...

Celestica initiated with an Overweight at Barclays

Celestica: The Unsung AI Champion

Stock Pickers Better Know When They're Going To Sell

Top 10 Quant Stocks Of 2024: Up Over 120%

Fabrinet initiated with Equal Weight at Barclays on valuation, rising competition

Fidelity Mid-Cap Stock Fund Q3 2024 Review

Bullish option flow detected in Celestica (CLS) with 9,734 calls trading, 1.4x expected, and implied vol increasing over 1 point to 51.34%. 11/29 w...

Celestica call volume above normal and directionally bullish

UBS initiated coverage of Celestica (CLS) with a Neutral rating and $95 price target The company is an artificial intelligence infrastructure leade...

Celestica initiated with a Neutral at UBS

Analysts have been eager to weigh in on the Technology sector with new ratings on Global Business Travel Group (GBTG – Research Report) and Celesti...

Comments

Celestica

Noticias

Últimas noticias sobre Celestica (NYSE:CLS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL